BANK VONTOBEL/CALL/BIOGEN IDEC/380/0.1/17.01.25 | Real-time Boerse Frankfurt Warrants 15:42:36 17/05/2024 BST | ||
| 0.033 EUR | -25.00% |
|
| Current month | -10.20% | ||
| 1 month | -30.16% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 0.033 | -25.00% |
| 16/05/24 | 0.044 | -65.08% |
| 15/05/24 | 0.126 | +50.00% |
| 14/05/24 | 0.084 | +10.53% |
| 13/05/24 | 0.076 | +22.58% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 03:42 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VM9C0P |
| ISIN | DE000VM9C0P2 |
| Date issued | 30/01/2024 |
| Strike | 380 $ |
| Maturity | 17/01/2025 (245 Days) |
| Parity | 10 : 1 |
| Emission price | 0.33 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.73 € |
|---|---|
| Lowest since issue | 0.016 € |
| Spread | 0.022 € |
| Spread % | 47.83% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230
USD
Average target price
285.9
USD
Spread / Average Target
+24.29%
- Stock Market
- Warrants
- Warrant
